Biotech Values

[swampboots]

"At R&R, Levitt seemed almost resigned to the fact that no single therapy is likely to triumph over AMD and that stabilization of vision is a more realistic goal."

For first time have let go of some original shares because absence of improvement expectations has smothered die hard hold on all shares.